Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia
Technology appraisal guidance
Reference number: TA891
Published:
Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin in early-April 2022.